EMEA-002066-PIP02-20 - paediatric investigation plan
talazoparib
PIPHuman
Pfizer Europe MA EEIG
Tel. +44 (0)1304 646 607
E-mail: pip_enquiries@pfizer.com
P/0130/2021: EMA decision of 14 April 2021 on the granting of a product specific waiver for talazoparib (Talzenna), (EMEA-002066-PIP02-20)